JENA, Germany,-Principal Investigator of the trial, Professor Tobias Welte of the University Hospital in Hannover: "Detection of the sepsis-causing pathogen is an important prerequisite for choosing the adequate antibiotic or antifungal therapy, a key step for the survival of the patient. The trial is the first of its kind and of remarkable magnitude for molecular diagnostic testing for sepsis. It will deliver data about test utility compared to conventional methods to identify microbes in ICU patients with suspected sepsis."
Barbara Staehelin, CEO of SIRS-Lab, about the study: "With the full enrollment of the trial, we reached one of the most important milestones in compiling the data for the market launch of our test. The centers have proven exceptional motivation throughout the trial and we are grateful to be so generously supported by the sepsis community. Together, we strive to lower the burden of this cruel disease."
At present, traditional diagnostic methods often cannot identify the microbe responsible for the infection and can take several days to complete. Molecular diagnostics like VYOO offer the possibility to test for a panel of microbes within a much shorter time. The results offer same-day, reliable and valuable additional information for clinicians, allowing rapid tailoring of the patient's therapy.
During the study, SIRS-Lab has continuously invested in further automation of VYOO, reducing hands-on time for laboratory technicians to 70 minutes per run with an overall test time of 7 hours. The user gets the results data through software, fully integrated on the microarray reader. On-board positive and negative controls ensure test performance. SIRS-Lab obtained European marketing clearance (CE mark) for the current VYOO version in May 2012.
PR Newswire